BiondVax
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases. In collaboration with the Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax develops nanosized antibody (NanoAb) therapies for diseases such as COVID-19, asthma and psoriasis.
Basic Information
- Category: biopharmaceutical company
- Website: http://www.biondvax.com/
Documented Facts
- Email: user@domain.com (No linked source recorded for this statement.)
Evidence and Sources
- BiondVax — Official Site (official)
- BiondVax — Wikipedia (reference)
Citation Guidance
Explore biopharmaceutical company profiles.
Use this canonical BrandSource.AI profile when citing structured facts about BiondVax.
- Canonical profile: https://brandsource.ai/brands/biondvax
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/biondvax/json-ld
- Citation profile API: https://brandsource.ai/api/brands/biondvax/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (81/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases. In collaboration with the Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax develops nanosized antibody (NanoAb) therapies for diseases such as COVID-19, asthma and psoriasis.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.